Open the lid on the problems facing global pharmaceutical giant Endo International plc and they start to look familiar. An insolvent US multinational laden with over $8 billion (€7.36 billion) in debt files for Chapter 11 bankruptcy in the Southern District of New York in August 2022.  In the background are thousands of opioid claims against the drugmaker, and antitrust suits too. Add Irish headquarters in Ballsbridge, Dublin, a proposed twin-track US-Irish restructuring process where first-lien creditors effectively take over the business and assets of the pharma group, and it all sounds a little like the Mallinckrodt bailout — another…

Want to continue reading?

Introductory offer: Sign up today and pay €200 for an annual membership, a saving of €100.

Subscribe

Cancel anytime.

Are you already a member? .